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Phosphoglycerate dehydrogenase (PHGDH) plays an essential role in cancer-specific metabolic reprogramming. It has
been reported as a putativemetabolic oncogene in several types of humanmalignant tumors, such as breast cancer and
melanoma. To date, PHGDH expression in colorectal cancer (CRC) as well as its association with clinicopathological
characteristics and prognostic implication remain undetermined. In this study, we determined the PHGDH protein
expressionusing tissuemicroarray immunohistochemistry (TMA-IHC) on193pairs of formalin-fixed, paraffin-embedded
specimens of CRC and adjacent tissues, 25 chronic colitis, 41 low-, and 19 high-grade intraepithelial neoplasia
specimens, and we also determined PHGDH mRNA level using quantitative reverse transcription PCR (qRT-PCR) on
additional 23 pairs of fresh CRC tissues and adjacent tissues.We found that both PHGDHmRNA and proteinwas highly
expressed in tumor tissues in comparison with matched adjacent non-tumor tissues, and high PHGDH protein
expressionwas correlatedwith advanced TNMstage (P= .038) and larger tumor (P= .001).Multivariate Cox regression
analysis showed that PHGDH protein expression (HR = 2.285, 95% CI = 1.18 to 4.41, P= .014), tumor differentiation
(HR = .307, 95% CI = .154 to 0.609, P = .001), and TNM stage (HR = 1.791, 95% CI = 1.125 to 2.85, P= .014) were
independent prognostic factors in CRC. Kaplan-Meier survival curves and log rank test showed that highPHGDHprotein
expression contributed to poor outcome in CRC patients (P b .001). In conclusion, these results suggest that
assessment of PHGDH expression could be useful in identifying a high-risk subgroup of CRC.
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Colorectal cancer (CRC) is the third most frequently diagnosed cancer
(1.4 million cases) with 694,000 deaths each year worldwide according
to GLOBOCAN 2012 [1,2]. Compared to Western Countries, China
does not have the highest CRC incidence rate. However, the incidence
andmortality of CRC have sharply increased in China over the past two
decades [3]. It was estimated that there were 274,841 new CRC cases
with 132,110 deaths in China in 2010 [3]. Despite considerable
advances in the treatments of CRC in recent years, the outcome of CRC
remains unfavorable. Given that the high incidence and mortality of
Figure 1. Differential level of PHGDH mRNA in colorectal cancer
(CRC) and adjacent normal tissues. Relative expression of PHGDH
mRNA was normalized to the internal reference gene GAPDH.
Preferential expression of PHGDH was observed in CRC tissues
over matched tumor-adjacent normal tissues (P b .0001).
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prognosis and clinical management of CRC.
Tumor cells are characterized by the uncontrolled growth, which
requires numerous nutrients to build cellular components including
amino acids, lipids, and nucleic acids [4–8]. It is hypothesized that
tumor cell reprograms the metabolic system to fulfill its demanding
specific biosynthetic requirements. One of known metabolic
adaptations of oncogenesis is that malignant cells have a tendency
to consume great amounts of glucose via fermentative metabolism in
order to produce plenty of serine and glycine, which normally are
converted to pyruvate, alanine, and lactates. Serine and glycine are
known as indispensible precursors for the production of other amino
acids, lipids, as well as nucleic acids. During this tumor specific
metabolic reprogramming, phosphoglycerate dehydrogenase
(PHGDH) plays a critical role by diverting the glycolytic metabolite,
3-phosphogycerate, into the serine biosynthetic pathway. Accumu-
lating studies have shown that some glycolytic enzyme, including
PHGDH, is commonly overexpressed in malignant cells [9–11], such
as breast cancer, melanoma, nasopharyngeal carcinoma, cervical
adenocarcinom as well as neuroglioma [5,12–16].
Two PHGDH transcripts have been found in human colon
adenocarcinoma [17], however the expression and prognostic
implication of PHGDH have not been fully elucidated in CRC. In
the current study, we evaluated both mRNA and protein expression
of PHGDH by qRT-PCR and TMA-IHC respectively on CRC tissue
samples. The association between PHGDH expression and the clinical
parameters and the prognosis of CRC patients were also evaluated.
Materials and methods
Clinical specimen collection
A cohort of 193 patients with colorectal carcinoma was recruited
from the Affiliated Hospital of Nantong University between January
2005 and December 2010. They were aged between 17 and 90 years,
and mean age was 65.2 years. All cases were newly diagnosed and
histopathologically confirmed through central pathology review by
light microscopy evaluation of diagnostic slides containing represen-
tative formalin-fixed or frozen tissues. In addition, 25 chronic colitis,
41 low-, and 19 high-grade intraepithelial neoplasia specimens were
collected as intestinal endoscopic biopsy. None of the patients have
been treated with chemotherapy or radiation therapy before receiving
surgical operation. Both tumor and matched peritumoral tissue
specimens were collected for the study. Medical records were searched
to collect the following data: age, gender, tumor site, histological type,
tumor differentiation, preoperative carcinoembryonic antigen (CEA)
level, TNM stage as well as tumor size (T), lymph node metastasis
(N), and distant metastasis (M). The study was approved by the
Ethics Committee of the Affiliated Hospital of Nantong University.
Quantitative reverse transcription polymerase chain reaction
To determine PHGDH mRNA level in CRC tissues, fresh CRC
cancer tissue and thematched tumor-adjacent normal tissue samples were
obtained from an independent 23CRC patients. Total RNAwas isolated
using TRIZOL (Invitrogen, CA, USA) and the cDNA was generated
using SuperScript® III Reverse Transcriptase (Invitrogen, CA, USA). The
qRT-PCR analysis was performed using Power SYBR® Green PCR
Master Mix (Invitrogen, CA, USA) according to manufacturer
instructions. The following primer pair was used to amplify PHGDH
(NM_006623): forward primer 5′-CACATTCTTGGGCTGAAC-3′
and reverse primer 5′-TTATTAGACGGTTATTGCTGTA-3′.Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was employed
as an internal control, while calculating the relative mRNA
expression level of PHGDH in the analyzed tissues (forward primer
5′-TGCACCACCAACTGCTTAGC-3′ and reverse primer
3′-GGCATGGACTGTGGTCATGAG-5′). All tests were run in
triplicate under standard condition of qPCR [18].
Tissue microarrays and immunohistochemistry
The tissue microarrays (TMAs) were built using a tissue array
instrument (Quick-Ray, UT06; UNITMA, Korea). Briefly, tissue cores
(2 mm in diameter) were punched from representative formalin-fixed
paraffin-embedded tissue and put in order in the TMA blocks.
Immunohistochemistry were performed to detect PHGDH protein
expression using protocols published elsewhere [19] with a primary
PHGDH antibody (ab117719, Abcam Inc. Cambridge, MA) and a
biotinylated antimouse secondary antibody (Zhongshan Golden Bridge
Biotechnology Co., Ltd., Beijing, China).
Evaluation of immunohistochemistry reaction intensity
To score the PHGDH immunostaining, the intensity of IHC
reaction on a TMAs was classified into 4 categories: 0, 1+, 2+, and
3+, which corresponded to no staining, weak staining, moderate
staining and strong staining, respectively. The product of staining
intensity score and the percentage of positive tumor cells (0% to
100%) was considered as the final score of PHGDH expression,
which ranged from 0 (no staining) to 300 (100% of cells with 3+
staining intensity). Then, a cutoff value with respect of overall survival
(OS) was generated using the X-tile software program (http://www.
tissuearray.org/rimmlab) [20] to further separate all samples into “low
or negative” PHGDH expression (PHGDHlow) and “high or positive”
protein expression (PHGDHhigh).
Statistical analysis
A student t-test was used for analysis of the distinction between
PHGDH mRNA expression in CRC and adjacent noncancerous
tissues. The association between PHGDH protein and clinicopath-
ological characteristics was tested using χ2 tests. Survival curves were
plotted using the Kaplan-Meier method and compared using the
log-rank test. Univariate and multivariate analysis were performed
using Cox proportional hazards model. The hazard ratio (HR) and
95% confidence interval (CI) were determined for each variable. The
SPSS 21.0 software was used for statistical analysis (SPSS Inc.,
Table 1. PHGDH expression in cancerous tissues and other tissues.
Characteristic Number PHGDHlow PHGDHhigh Pearson χ2 P value
Chronic colitis 25 20(80.0) 5(20.0)
Low grade intraepithelial neoplasia 41 25(61.0) 16(39.0)
High grade
intraepithelial neoplasia
19 6(31.6) 13(68.4) 10.578 0.005
Cancer 193 75((38.9) 118(61.1)
Surgical margin 183 145(79.2) 38(20.8)
Total 461 271(58.8) 190(41.2) 73.742 b0.001
P b .05.
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was considered statistically significant.
Results
The expression of PHGDH in CRC and paired
nonmalignant tissues
Immunohistochemistry showed that positive staining of PHGDH
protein was mainly localized in the cytoplasm of cells (Figure 1). High
expression of PHGDH was observed in a significantly larger
percentage of benign tissues (high grade intraepithelial neoplasia)
versus chronic disease tissues (chronic colitis) (P = .005). Consis-
tently, tumor tissues were significantly more likely to show high
PHGDH expression than adjacent normal tissues (surgical margin)
(P b .001): high PHGDH expression was detected in 118 of the 193
CRC tissues (76.1%) and in 38 of the 183 matched tumor-adjacent
normal tissues (20.8%) (Table 1).
Moreover, we also performed a comparison of PHGDH mRNA in
a cohort of 23 pairs of tumor tissues and their adjacent normal tissues.
The relative expression level of PHGDH was normalized to the
expression of endogenous gene GAPDH. Similar to the proteinFigure 2. Representative TMA-IHC staining of PHGDH. (A1, A2) colore
cells; (B1, B2) high-grade intraepithelial neoplasia with positive stain
staining; (D1, D2) normal intestinal mucosa. Original magnification ×
B2, C2, and D2. Red and green arrows point to positive and negativeexpression pattern, PHGDH mRNA level was significantly elevated
in CRC (Figure 2) tissues compared to normal tissues (P b .0001).
Correlation of PHGDH expression with clinicopathological
characteristics of CRC patients
To evaluate clinicopathological implication of PHGDH expres-
sion, we correlated PHGDH expression with following variables:
tumor site, histological type, tumor differentiation, CEA level, TNM
stage. High PHGDH expression was associated with CRC stage
(stage III+IV, P = .038) and tumor size (P = .001) (Table 2).
Clinical outcome
Table 3 shows the results of the univariable and multivariable
models for 5-year overall survival (OS).
Among the analyzed clinicopathological variables, differentiation
(HR = 0.307, 95% CI = 0.154 to 0.609, P = .001) and TMN (HR =
1.791, 95% CI = 1.125 to 2.85, P = .014) were associated with poor
5-year OS. Poor differentiation and advanced TNM stage (III+IV)
were independent predictors for unfavorable prognosis in CRC. More
importantly, multivariate analysis indicated a survival disadvantage of
CRC with high levels of PHGDH at a HR of 2.285 (95% CI = 1.18
to 4.41, P = .014) for 5-year OS, providing evidence of the prognostic
value of PHGDH in CRC.
Accumulative survivals for all patients were visualized by the
Kaplan-Meier survival curves. Survival of patients with high PHGDH
levels was worse than that of patients with low PHGDH levels during
the 5-year follow-up period. The estimated 5-year OS rate was 52%
and 80% respectively (Figure 3, A). Statistical analysis demonstrated
that high PHGDH levels were associated with a significantly worsen
5-year OS (log-rank test: P b .001; Figure 3, A). In other words, in
193 patients with CRC, dichotomized PHGDH level by the cut off value
of 120 was a significant prognostic factor of overall survival (P = .0002).ctal adenocarcinoma, with strong PHGDH staining in cytoplasm of
ing; (C1, C2) low-grade intraepithelial neoplasia with weak positive
40 (bar = 500 μm) in A1, B1, C1, and D1; ×400 (bar = 50 μm) in A2,
PHGDH staining, respectively.
Table 2. Relationship between the expression of PHGDH and clinicopathological characteristics in
colorectal cancer.
Characteristic n PHGDHlow PHGDHhigh Pearson χ2 P
Total 193 75(38.9) 118(61.1)
Gender 0.003 0.954
Male 124 48(38.7) 76(61.3)
Female 69 27(39.1) 42(60.9)
Age 1.228 0.268
b60 63 28 (44.4) 35(55.6)
≥60 130 47(36.2) 83(63.8)
Location 0.070 0.792
Colon 141 54(38.3) 87(61.7)
Rectum 52 21(40.4) 31(59,6)
Histological type 0.642 0.423
Tubular and Papillary 174 66(37.9) 108(62.1)
Other a 19 9(47.4) 10(52.6)
Differentiation 2.230 0.135
Poor 18 4(22.2) 14(77.8)
Well and middle 169 68 (40.2) 101(59.8)
Other b 6 3 3
TNM stage 6.529 0.038
0-I 35 20(57.1) 21(42.9)
II 81 26(32.1) 49(67.9)
III +IV 77 29(37.7) 48(62.3)
T 10.717 0.001
Tis+ T1+ T2 41 25(61.0) 16(39.0)
T3, 4b 152 50(32.9) 102(67.1)
N 0.128 0.938
N0 118 47(39.8) 71(60.2)
N1a 38 14(36.8) 24(63.2)
N1b,1c,2a,b 37 14(37.8) 23(62.2)
Preoperative CEA, ng/ml 2.696 0.101
≤15 116 50(43.1) 66(59.6)
N15 27 7(25.9) 20(74.1)
Unknown 50 18 32
a Others: Mixed (Tubular and mucinous or signet) adenocarcinoma, 10 cases; Mucinous carcinoma,
6 cases; signet ring cell carcinoma, 1 case; Adeno-squamouscarcinoma, 1 case. Squamouscarcinoma, 1 case.
b Others: Mucinous carcinoma, 4 cases; Signet ring cell carcinoma, 1 case. squamouscarcinoma, 1 case.
P b .05.
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Metabolic reprogramming has been recognized as a fundamental
event in tumorigenesis [4,6,21,22]. Cancer cell proliferation is not
limited by ATP production but rather by the ability of cells to
generate lipids, nucleic acids, and proteins needed to support theTable 3. Univariate and multivariable analysis of prognostic factors for 5-year survival in colorectal c
Univariate analysis
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PHGDH expression
High versus low and none











Tubular and Papillary versus Others a
0.855 .715 0
Differentiation
Poor versus Well and Middle
0.201 b .001 0
TNM stage
0 and I versus II versus III and IV
2.493 b .001 1
T
Tis and T1 and T2 versus T3 and 4b
24.144 .002 3
N
N0 versus N1a versus N1b and N2a and 2b
1.685 b .001 1
Preoperative CEA, ng/ml ≤15 versus N15 2.354 .004 1
P b .05.
a Others: Mixed (Tubular and mucinous or signet) adenocarcinoma, 10 cases; Mucinous carcinoma, 6 caserapid growth of biomass. Cancer cells prefer aerobic glycolysis which
allows them to adapt metabolism to satisfy an increased biosynthetic
need [4,9,23,24]. Despite the numerous evidence of the fundamental
role of metabolic reprogramming in carcinogenesis, such metabolic
alternation has not been confirmed in human CRC. Since PHGDH
has been well known to initiate de novo serine synthetic pathway, it
may act as a surrogate marker of serine biosynthetic activity in CRC.
With this in mind, we compared PHGDH expression in CRC and
matched adjacent normal tissues and explored its clinicopathological
correlation and prognostic value. RNA and protein levels of the
PHGDH were shown to be elevated in tumors in this study. CRC
patients with tumors of high PHGDH expression levels tended to
have stage III/IV CRC and larger tumors. Moreover, we demon-
strated that high PHGDH level was significantly associated with
inferior survival in CRC, and PHGDH expression has prognostic
value in CRC.
Several studies have linked PHGDH expression levels with the
activity of serine biosynthesis. PHGDH activity was found to be
proportionally correlated with the overall capacity of serine
biosynthesis in rat tissues [25]. Serine synthesis-associated enzyme
assay provided evidence of remarkable increases in the activities of
PHGDG and serine hydroxymethyltransferase in human carcinomas
and transplantable rat sarcomas, suggesting increased capacity of
serine synthesis in cancer [26]. A more recent study using isotope
labeling and kinetic profiling analysis demonstrated that high
PHGDH expression can push metabolic flux into the serine pathway;
while RNA interference-mediated knockdown of PHGDH can keep
glycolytic intermediates from entering serine metabolism pathway in
human PHGDH-amplified cancer cell lines [5].
PHGDH has been identified as a frequently amplified gene in a
high-resolution analysis of somatic copy-number alterations on 3131
cancer samples of 26 histological types [5,27], recurring copy number
gains of PHGDH have been seen in 40% of melanomas and 16% of
all cancers [5,27]. In melanoma, recurrent PHGDH gene copy
number gain was associated with increase in protein levels [5].
Similarly, PHGDH gene was amplified in 70% of estrogen receptor
(ER)-negative breast cancers [12]. Mechanistic studies indicated thatancer.
Multivariate analysis
5% CI HR P N|z| 95% CI





.112 0.360 0.307 0.001 0.154 0.609




s; Signet ring cell carcinoma, 1 case; Adeno-squamouscarcinoma, 1 case. Squamouscarcinoma, 1 case.
Figure 3. Kaplan-Meier survival curves of CRC patients. (A) Overall
survival time in patients with tumor expressing high PHGDH levels
(green) was significantly shorter than those with tumor expressing
low PHGDH levels (blue). (B) Patients with well and moderately
differentiated tumors (green) tended to survival longer than those
with poorly differentiated tumors (blue). (C) Advanced TNM stages
(brown, II; green, III+IV) were significantly associated with worse
overall survival.
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can drive cells toward malignant transformation by interrupting
acinar morphogenesis and the formation of polarity, and maintaining
anchorage-independent growth [5]. Stable PHGDH knockdown
using shRNA significantly reduces proliferation rate in an esophageal
squamous cell carcinoma cell line and a melanoma cell line, which
have naturally acquired a high copy number gain of PHGDH [5].
Further, the study showed that the inhibited proliferation was a result
of impaired serine biosynthesis [5]. High PHGDH expression
generally results in increased glycolytic metabolite flux into serine
pathway, vice versa [5].
In addition to catalyzing de novo serine synthesis, PHGDH may
also promote carcinogenesis by producing d-2-hydroxyglutarate
(d-2HG) [28], an oncometabolite [29–32]. PHGDH knockdown
was shown to reduce cellular 2HG by approximately 50% inseveral PHGDH-amplified breast cancer cell lines, and PHGDH
overexpression enhanced cellular 2HG over 2-fold in several
non-PHGDH-amplified breast cancer cells [28]. Recently, Fan et al.
reported that PHGDH could also convert α-ketoglutarate to the
d-2HG through NADH-dependent reduction [28].
Apart from its role in carcinogenesis, PHGDH has also been
implicated in cancer prognosis. Among breast cancer MDA-MB-231
cell line variants, the bone metastatic propensity is associated with
upregulation of three serine biosynthesis pathway-associated genes,
PHGDH, phosphoserine aminotransferase 1 (PSAT1), and phos-
phoserine phosphatase [13]; elevated expression of PHGDH and
PSAT1 in primary breast cancer was significantly associated with poor
prognosis [13]. The prognostic implications of serine metabolism-
associated enzymes have been studied in a bioinformatic analysis
involving 17 breast and 7 lung cancer publically available datasets
[33]. PHGDH was identified as a predictor for unfavorable prognosis
in breast cancer but not in lung cancer, suggesting potential tissue-
specific roles for PHGDH. With 54 human cervical adenocarcinoma
samples, Jing et al. observed significantly higher PHGDH expression in
tumors than in normal cervical glandular epithelium, and high
PHGDH expression conferred significant survival disadvantage in
cervical adenocarcinoma [16]. Recently, Yoon et al. examined the
serine metabolism-associated enzymes in a cohort of Korean patients
with colon cancer [10]. They found that the expression levels of
pyruvate dehydrogenase kinase (PDK) 1, phosphoserine aminotrans-
ferase and PHGDH were significantly elevated in colonic tumor
tissues, when compared to those in paired normal tissues. However, the
prognostic significance of these enzymes for survival was not
demonstrated statistically although univariate analysis indicated that
PDK1 was significantly associated with overall survival [10]. This may
be associated with the sources of primary antibody, patient cohort as
well as cutoff setting for IHC score.
Conclusions
In conclusion, we found that PHGDH was overexpressed in CRC
tissues and the high expression of PHGDH protein was correlated
with TNM stage and tumor size, and also was an independent predictor
for unfavorable prognosis in CRC.
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